04 Apr 2016


Singapore – April 4, 2016 – HYK Gene and Vishuo Biomedical signed a Strategic Alliance Agreement today.
HYK Gene manufactures and distributes PSTAR (high-throughput sequencing system), which is the only CFDA-approved NGS analyser with independent intellectual property. HYK Gene also offers proprietary clinical tests for risk assessment and pharmacogenetics of Alzheimer’s disease, cancers and cardiovascular diseases. Vishuo Biomedical develops automated analysis pipeline and clinical annotation database for sequencing data to support clinical decision-making. Vishuo Biomedical is also developing solution to integrate PoC and clinical data to build more accurate model for disease risk prediction and prognosis management. Together, the two companies provide complete solution for the entire workflow of precision medicine. This alliance brings together their respective strengths to drive market across APAC region.

Asia-Pacific region, with over 4.4 billion people in 2015, consists of nearly 60% of the world’s population. Being an ethic-diverse region, it poses unique challenge and great potential for precision medicine. In 2014, the region accounted for nearly two-thirds of global economic growth. It will remain to be the growth engine of the world economy in the foreseeable future. The health issues risen with rapid industrialization and urbanization have been recognized by governments across the region, and the demand for better healthcare has never been higher and more urgent. Total APAC healthcare spending is expected to grow at a CAGR 10.5% to reach 2.2 trillion USD in year 2018.

About HYK Gene

HYK Gene, a leading global precision medicine and gene sequencing system solutions provider based in Shenzhen, was founded in 2008 by high-level overseas talents from the ‘Thousand Talents Program and the National Distinguished Experts team. HYK-PSTAR-IIA high throughput clinical sequencing system, is the first “Created-in-China” with independent intellectual property. HYK Gene has complete capacity for product R&D and production in house, and is providing clinical diagnostic services to numerous customers in China. HYK Gene devotes to offer the highest quality products and exceptional experience to all customers, and dedicates to advance healthcare in China through technology and innovation.

About Vishuo Biomedical

Vishuo Biomedical Pte Ltd is a Singapore based healthcare technology company formed in 2011, dedicated to provide precision medicine for prognosis, diagnosis and treatment. Our vision is to organize and analyse world’s pathological big data and optimize treatment for clinicians and patients.
Our core product, iCMDBTM, advances customized analysis of diseases on molecular level tailored to clinicians in conducting personalized treatment based on patients’ genetic and pathology profiles. To date, there are more than 200 diseases, 750 treatments and 1200 biomarkers in the datasets, all datasets are constantly reviewed and validated by experts in life sciences and medical consultants. To ensure good management of patient data, we protect and encrypt confidential personal information by deploying on-site server installed with iCMDBTM platform and customize analysis pipelines to generate automated data quality reports and clinical annotation reports for supporting clinical decision-making.